Global Blood Therapeutics Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- Global Blood Therapeutics's estimated annual revenue is currently $24M per year.
- Global Blood Therapeutics received $115.0M in venture funding in December 2017.
- Global Blood Therapeutics's estimated revenue per employee is $70,044
- Global Blood Therapeutics has 343 Employees.
- Global Blood Therapeutics grew their employee count by 60% last year.
- Global Blood Therapeutics currently has 28 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Advanced Cell D...||$27.6M||178||8%||N/A|
|The J. Craig Ve...||$33.3M||215||N/A||N/A|
What Is Global Blood Therapeutics?
Global Blood Therapeutics (GBT) (NASDAQ: GBT), based in South SF, is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. We aim to make a significant impact by treating the root cause or making a meaningful difference in the standards of care. Through in-licensing and continued research and development, were committed to Hope+Science+Community. You can view our social community guidelines at http://www.gbt.com/about/social-community-guidelines/keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
|Martine Kraus||Vice President, Regulatory Affairs|
|Irwan Anwar||Senior Manager Supply Chain Planning|
|Brian Cathers||Chief Scientific Officer|
|Fang Wang||Head Of Chemical Development|
|Gwendolyn Whitney||Vp, U.s. Commercial Operations|
|Patrick Hall||Head Of Managed Care & Reimbursement|
|Ted Love||President & Ceo|
|Xiang Wang||Associate Director|
|Marcus Hinton||Regional Business Director|
|Sarah Thayer||Executive Director, Clinical Operations at Global Blood Therapeutics|
Global Blood Therapeutics News
Global Blood Therapeutics is preparing to “go-it-alone” in commercialization. I provide my three reasons why the company can handle the ...
05, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that the U.S. Food and Drug ...
After disclosing that the Food and Drug Administration has accepted the company's application to review its lead product candidate for approval ...
Global Blood Therapeutics Funding
|2016-06-21||$115.0M||Undisclosed||J.P. Morgan Securities LLC||Article|
|2016-06-27||$112.3M||Undisclosed||J.P. Morgan Securities LLC||Article|
|2017-02-23||$125.0M||Undisclosed||Cantor Fitzgerald & Co||Article|
|2017-03-01||$143.8M||Undisclosed||Cantor Fitzgerald & Co||Article|
|2017-12-18||$115.0M||Undisclosed||Cantor Fitzgerald & Co.||Article|
Global Blood Therapeutics Executive Hires
|2014-06-18||Ted W. Love||CEO||Article|
|2014-08-05||Hing Sham||SVP Chemistry||Article|
|2015-04-15||Jung E. Choi||Chief Business/Strategy Officer||Article|
|2016-10-13||Tricia Suvari||Chief Legal Officer||Article|
|2018-03-07||David Johnson||Chief Commercial Officer||Article|
|2018-08-22||Heidi L Wagner||SVP Government Affairs and Policy||Article|